NASDAQ:ACIU - AC Immune Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.67 +0.12 (+1.04 %)
(As of 12/12/2018 11:07 AM ET)
Previous Close$11.55
Today's Range$11.22 - $12.50
52-Week Range$7.16 - $17.40
Volume125,579 shs
Average Volume115,832 shs
Market Capitalization$734.37 million
P/E Ratio-38.90
Dividend YieldN/A
Beta1.22
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
Previous Symbol
CUSIPN/A
Phone41-21-345-9121

Debt

Debt-to-Equity RatioN/A
Current Ratio19.22
Quick Ratio19.22

Price-To-Earnings

Trailing P/E Ratio-38.90
Forward P/E Ratio-13.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.58 million
Price / Sales49.33
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.09 per share
Price / Book5.58

Profitability

EPS (Most Recent Fiscal Year)($0.30)
Net Income$-26,840,000.00
Net Margins-146.09%
Return on Equity-24.14%
Return on Assets-21.48%

Miscellaneous

Employees86
Outstanding Shares65,860,000
Market Cap$734.37 million
OptionableNot Optionable

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.04. The firm earned $2.34 million during the quarter, compared to analysts' expectations of $1.71 million. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

3 Wall Street analysts have issued 12-month target prices for AC Immune's stock. Their predictions range from $14.00 to $18.00. On average, they expect AC Immune's stock price to reach $16.6667 in the next twelve months. This suggests a possible upside of 42.8% from the stock's current price. View Analyst Price Targets for AC Immune.

What is the consensus analysts' recommendation for AC Immune?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

Has AC Immune been receiving favorable news coverage?

News headlines about ACIU stock have been trending positive recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AC Immune earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of AC Immune's key competitors?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 60)
  • Mr. Joerg Hornstein, Chief Financial Officer
  • Dr. David A. Lowe, Interim Chief Scientific Officer (Age 71)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 47)
  • Dr. Andreas Muhs, Chief Scientific Officer (Leave of Absence) (Age 56)

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (7.91%), Janus Henderson Group PLC (2.53%), Artal Group S.A. (1.14%), PointState Capital LP (0.86%), Sphera Funds Management LTD. (0.76%) and Citadel Advisors LLC (0.43%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP and Cohen Lawrence B.

Which institutional investors are buying AC Immune stock?

ACIU stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Sphera Funds Management LTD., Citadel Advisors LLC, Artal Group S.A., State of New Jersey Common Pension Fund D, Belpointe Asset Management LLC and Compagnie Lombard Odier SCmA.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $11.67.

How big of a company is AC Immune?

AC Immune has a market capitalization of $734.37 million and generates $15.58 million in revenue each year. The company earns $-26,840,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. AC Immune employs 86 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is http://www.acimmune.com.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]


MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Candlestick

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel